Core Viewpoint - Australia Huaren Endoscopy (688212.SH) expects a revenue increase for 2025, but a significant decline in net profit due to changes in product sales structure and increased operational costs [1] Financial Projections - The company anticipates 2025 revenue between 764.31 million and 774.39 million CNY, representing an increase of 14.76 million to 24.84 million CNY, or a growth of 1.97% to 3.31% year-on-year [1] - The expected net profit attributable to shareholders for 2025 is projected to be between 8.05 million and 11.58 million CNY, reflecting a decrease of 9.43 million to 12.96 million CNY, or a decline of 44.89% to 61.69% year-on-year [1] - The net profit after deducting non-recurring gains and losses is expected to be between -10.53 million and -7 million CNY for the same period [1] Operational Insights - The company has experienced a phase change in its product sales structure, leading to a decline in overall gross margin [1] - To strengthen long-term competitiveness, the company is increasing investments in marketing system development, brand influence enhancement, product iteration, and new technology research and development [1] - Despite revenue growth, the company faces profit decline due to high expenditures in sales, management, and R&D [1]
澳华内镜(688212.SH)：预计2025年度净利润同比下降44.89%到61.69%